A rev/β-galactosidase fusion protein binds in vitro transcripts spanning the rev-responsive element of human immunodeficiency virus type 1 (HIV-1)  by Aepinus, Christian et al.
Volume 263, number 2, 217-221 FEBS 08331 April 1990 
A rev/p-galactosidase fusion protein binds in vitro transcripts 
spanning the rev-responsive lement of human immunodeficiency virus 
type 1 (HIV-l) 
Christian Aepinus, Reinhard Voll, Michael Broker* and Bernhard Fleckenstein 
Institut fiir KIinische und Molekulare Virologie, Universitiit Erlangen-Niirnberg, D-8S20 Erlangen and *Behringwerke AG, 
D-3550 Marburg, FRG 
Received 2 1 February 1990 
The rev protein of human immunodeficiency virus type 1 (HIV-l), a phosphoprotein of 20 kDa apparent molecular mass, is essential to target 
the mRNA for virion polypeptides into the cytoplasm. This effect is mediated by a specific RNA stretch (rev-responsive element = RRE) localized 
within a 3’-terminal segment of the mRNA encoding virion proteins. We present evidence that rev expressed as a p-galactosidase fusion protein 
in E. coli forms a complex with in vitro transcripts containing the RRE; it can be precipitated by monoclonal antibodies with rev or b-galactosidase 
specificity. In addition, specific binding of rev protein to RNA could be demonstrated by Northwestern blotting. 
Rev-protein; Human immunodeficiency virus type 1; Sequence-specific RNA-binding; Rev responsive element; Immunoprecipitation; 
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1. INTRODUCTION 
Gene expression of human immunodeficiency virus 
(HIV) is regulated by a number of viral and cellular fac- 
tors [ 1,2]. The rev protein, one of the important viral 
regulatory polypeptides, is encoded by a double-spliced 
mRNA [3,4]; it is a phosphoprotein of approximately 
20 kDa that has been shown to be essential for the ex- 
pression of viral structural proteins [4,5]. If expression 
plasmids are transfected into cell cultures, the rev 
polypeptide appears to be accumulated in the nucleus, 
particularly in the nucleoli [6-lo]. There is evidence 
that rev functions by supporting transport to cytoplasm 
of single-spliced and unspliced (i.e. genomic) HIV-l 
transcripts [4,5,7,1 l-141. Furthermore, a role in 
mRNA stabilization and translation of these messages 
has been demonstrated [7,14]. Phosphorylation that is 
performed by an intranuclear kinase at serine residues 
appears not to be required for rev function, at least not 
for cytoplasmic RNA targeting [ 10,15- 171. 
A &-acting element hat is essential and sufficient to 
mediate the rev effect has been mapped in the 3 ‘-half 
of the env mRNA [14,18]. More precisely, it cor- 
responds to a StyI-Sau3A fragment of 210 bp coding 
for the N-terminus of the transmembrane glycoprotein 
gp 41 [13]; the target has been termed c&acting rev- 
responsive sequence (CAR) [18] or rev-responsive le- 
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ment (RRE) [13,14]. The element has a stable stem- 
loop structure; it is conserved among all HIV isolates 
investigated so far [13]. The effects of rev were in- 
dependent of the presence of splice donor/acceptor 
sites [7,13]. To be active, the c&acting element needs 
to be in sense orientation of the message; it is func- 
tional, if CAR/RRE is localized in an intron or exon 
structure [ 131. Trans-dominant negative repressors of 
the rev function were created by site-directed 
mutagenesis of the rev reading frame, suggesting that, 
akin to transcription factors [19], the rev polypeptide 
has two domains. One may be required for RNA bin- 
ding and one for another function related to RNA 
targeting. Recently, specific interaction of pro- 
karyotically expressed unfused rev peptide with the 
RRE has been shown by RNase-protection [20] and by 
filter-binding and gel-shift assays [21]. This study pro- 
vides evidence for a direct and specific in vitro binding 
of a rev/P-galactosidase fusion protein to the RRE. 
These rapid procedures hould help to facilitate further 
investigations of rev and RRE interaction. 
2. MATERIALS AND METHODS 
2.1. Cloning procedures and prokaryotic expression 
The reading frames for HIV-l regulatory proteins rev, tat, and nef 
were inserted into the prokaryotic expression vector PROS [22]. 
Restriction fragments coding for HIV-l regulatory proteins were 
taken from the cDNA plasmid pCV-1 [3] that was kindly provided by 
F. Wong-Staal. Ligation was performed with blunt-ended fragments 
(Dpnl) or after filling m recessed ends (Xhol, HindIII, HinfI, SfanI) 
[23]. The expression plasmid pRVA was constructed with a 266 bp 
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HinfI fragment, the plasmid pRVB by inserting a 599 bp Sfanl frag- 
ment into PROS (Fig. 1). The resulting fusion proteins are composed 
of 375 N-terminal amino acids of E. coli @-galactosidase, a cleavage 
site for the protease factor Xa (FXa), 12- 17 amino acids from the 
polylinker of PROS, followed by HIV-l specific sequences. The pro- 
teins encoded by the vector pTAT contain the amino acids 4-86 of 
the tat polypeptide. PRVA specifies amino acids 17-104 of rev, 
pRVB the amino acids 2-116 of rev, and pNEF the amino acid 
residues 36-206 of the nef-polypeptide. Fusion proteins were purified 
from transformed E. coli BMH 71-18 [24] as published by Nagai et 
al. [25]. All expression plasmids were verified by DNA sequencing 
[26]. The induced fusion proteins and their FXa cleavage products 
were checked by SDS-polyacrylamide gel electrophoresis. 
2.2. In vitro transcription 
The blunt-ended Sty1 fragment spanning the RRE from position 
7358 to 7628 of HIV-l clone BHlO [27] was inserted into the SmaI 
site of the vector PBS (Stratagene, Heidelberg). The resulting clone 
p14STM-4 was used for in vitro transcription as published by Krieg 
and Melton [28]. The T7 polymerase transcripts from SalI-cut 
plasmid p14STM-4 consist of 312 nucleotides and correspond to the 
sense-orientated RRE. Bacteriophage Tj RNA polymerase transcripts 
from the EcoRI-cleaved clone pSTl4M-4 had 330 nucleotides and an- 
tisense orientation. The transcripts were labeled by the addition of 
50 &i [LU-“P]UTP (400 pCi/mmol; Amersham, Braunschweig). 
Radioactivity was quantified by Cerenkov counting for each 
transcript; the quality of RNA was analysed in denaturing 6% 
polyacrylamide gels. 
2.3. Monoclonal antibodies and immunoprecipitation 
The monoclonal antibodies directed against rev (mab 111, 348) [9] 
and/%galactosidase (mab 87.55/60) [27] were purified through a pro- 
tein A Sepharose column (Pharmacia, Uppsala) [30]. RNA/protein 
complexes were precipitated with the monoclonal antibodies as 
described [31]. In vitro transcripts from clone p14STM-4 (lo6 cpm) 
were incubated in a volume of 10 pl with approximately 10 pg of the 
fusion proteins for 30 min at 0°C prior to reaction with monoclonal 
antibodies and subsequent precipitation with Pansorbin cells 
(Calbiochem, Frankfurt). Protein/RNA incubation was performed 
in NET-2 buffer (100 mM NaCl/SO mM Tris, pH 7.4; 2SOpM/ml 
RNasin and 0.3% vanadyl ribonucleotide complexes (VRC)) in 4 M 
urea and 0.05% NP40. Pansorbin cells were suspended in NET-2 buf- 
fer in the presence of 200 gg/ml E. coli tRNA (=3 x lo-’ mol/ml) 
as nonspecific competitor. Washing was done in NET-2 for 5 times. 
2.4. Northwestern blotting 
Demonstration of RNA/protein binding was performed by 
Northwestern blotting essentially as published [32,33]. The fusion 
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Fig. 1. Structure of the prokaryotic expression clones pRVA (for rev fragment), pRVB (for rev), pTAT, and pNEF. The plasmids are derived 
from the cDNA clone pCV-1 [3]. The numbering of the base pairs and relevant restriction enzymes is according to [3]. Open segments, expressed 
HIV-specific cDNA sequences; thin lines adjacent to open segments, nontranslated HIV-specific cDNA sequences. 
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proteins from E. coli were purified [25], separated by 12.5% (w/v) 
polyacrylamide gels, blotted to nitrocellulose (NC) filters, and were 
allowed to react with 32P-labeled in vitro transcripts of sense or an- 
tisense orientation. NC-strips after blot procedures were prein- 
cubated for 1 h in probing buffer (50 mM NaCl; 10 mM Tris, pH 
7.5; 1 mM EDTA; 0.02% bovine serum albumin (BSA); 0.02% 
Ficoll; 0.02% polyvinylpyrrolidone). Incubation was performed in 
the same buffer for 1 h and 1 x lo6 cpm of either transcript added. 
To lower nonspecific background E. coli tRNA in a concentration of 
20 @g/ml (-3 x 10m6 mol/ml) was present in the incubation reaction. 
Washing was done 3 times in probing buffer without BSA. Immuno- 
staining of NC-strips post-exposure by rev-mab 348 has been describ- 
ed 191. 
3. RESULTS 
3.1. Binding of HIV-l rev protein to in vitro 
transcripts can be demonstrated by an immuno- 
precipitation assay 
To substantiate the hypothesis of direct RNA bin- 
ding by the rev polypeptide, we tried to precipitate an 
RNA/protein complex with monoclonal antibodies. 
Labeled in vitro transcripts from clone p14STM-4 
spanning the RRE (Fig. 2) were incubated with the fu- 
sion protein derived from the expression vector pRVB 
and immunoprecipitated by monoclonal antibodies. 
Fig. 3, lane 2, shows that the expected RNA/protein 
complex is formed in vitro, since the radioactive 
transcript is precipitated by the rev specific monoclonal 
antibody (rev-mab 348). The same complex could also 
be detected using the monoclonal antibody (mab 
87-.55/60) that is directed against the N-terminal part of 
P-galactosidase within the fusion protein (Fig. 3, lane 
5). No significant amounts of radioactive RNA were 
precipitated by either monoclonal antibody, if 
antisense-transcripts were incubated with the rev- 
specific fusion protein (Fig. 3, lanes 4 and 6) or if pro- 
karyotic protein was missing (Fig. 3, lanes 1 and 3). 
Reaction of the monoclonal antibody rev-mab 348 with 
the fusion protein prior to the incubation with in vitro 
transcripts prevented appreciable precipitation of sense 
or antisense RNA (Fig. 3, lanes 7 and 8, respectively). 
This suggests that the binding site of the monoclonal 
antibody rev-mab 348 is in close vicinity to the RNA 
binding domain of the rev polypeptide, or that interac- 
tion of the fusion protein with rev-mab 348 results in 
changes of the secondary/tertiary structure, thus in- 
hibiting complex formation with RNA. The fusion pro- 
teins from the expression plasmids pTAT and pNEF 
did not bind to either type of in vitro transcribed RNA 
(data not shown). Fusion protein from expression 
plasmid pRVA, lacking the 17 N-terminal amino acids 
of rev, showed diminished binding (data not shown). 
3.2. Interaction between a prokaryotic rev-& 
galactosidase fusion protein and in vitro 
transcribed RNA is visualized by North western 
blotting 
The partially purified fusion proteins from the pro- 
karyotic expression clones (Fig. 1) were separated by 
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Fig. 2. The reading frames of HIV-l and map position of a S&I- 
Suu3A fragment containing the rev responsive element (RRE). Major 
splice donor (SD) and splice acceptor (SA) sites for tat and rev 
mRNA are indicated. 
polyacrylamide gels, transferred to nitrocellulose, and 
incubated with the radioactive in vitro transcripts from 
plasmid p14STM-4. Fig. 4, lane b, shows significant 
complexing of labeled sense RNA to the fusion 
polypeptide from clone pRVB. The signal obtained 
with the fusion protein pRVA was equal to pRVB in 
repeated experiments (Fig. 4, lane c). Equal amounts of 
radioactivity in antisense orientated transcripts did not 
result in visible binding. Neither sense nor antisense 
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Fig. 3. Demonstration of RNA/protein binding by 
immunoprecipitation of rev protein/RNA complexes with 
monoclonal antibodies. In vitro transcripts in sense orientation (lanes 
1, 2, 5, 7) and in antisense direction (lanes 3, 4, 6, 8) were incubated 
with fusion protein from clone pRVB. Precipitation with mab 348 
against rev (lanes 1, 2, 3, 4, 7, 8) and with mab 87-55160 directed 
againstfl-galactosidase (lanes 5, 6). For lanes 7 and 8, the monoclonal 
antibody was allowed to react with pRVB protein prior to RNA 
incubation. Fusion protein was omitted in lanes 1 and 3. The size of 
full length transcripts corresponds to 312nt (sense) and 330nt 
(antisense), respectively. The smaller RNAs apparently resulted from 
degradation and radiolysis during experimental procedures. M, DNA 
size markers. 
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Fig. 4. Northwestern blot to demonstrate specific binding of RRE 
sense transcripts with prokaryotic rev fusion protein. Partially 
purified proteins from expression plasmids pNEF (lanes a, f), pRVB 
(lanes b, g), pRVA (lanes c, h), pTAT (lanes d, i) and marker proteins 
(lanes e, j) blotted to NC. Lanes a-e are an autoradiography post- 
incubation with RRE sense transcripts (antisense RRE incubated 
strips showed no real hybridization signal, therefore data not shown). 
Lanes f-j are the same strip after immunostaining with rev-mab 348. 
In addition, efficiency of protein transfer by blotting was checked 
after exposure by Ponceau S staining. M are marker proteins, 
numbers are molecular mass of marker proteins in kDa. 
transcripts reacted with the fusion proteins from pTAT 
and pNEF, where the ,&galactosidase component is 
identical to the pRVB-derived polypeptide (Fig. 4). 
4. DISCUSSION 
This study has shown by two independent techniques 
that a rev-specific polypeptide can specifically bind to 
RNA containing the rev-responsive element (RRE) of 
human immunodeficiency virus type 1. The two pro- 
cedures, Northwestern blot and immunoprecipitation 
by monoclonal antibodies against rev, are based on in 
vitro assays that are conducted under quite distinct buf- 
fer conditions. Sense-transcripts are reacting with rev- 
specific proteins expressed in E. coli, but antisense 
transcripts do not. It indicates that a rev polypeptide is 
able to bind RNA in a sequence-specific fashion in the 
absence of other viral or cellular proteins. It may be 
concluded that the binding of rev protein to the RRE 
is a functionally important step in cytoplasmic 
targeting of mRNA for the structural proteins of im- 
munodeficiency viruses. 
In vitro mutagenesis of eukaryotic rev expression 
vectors revealed some mutants that were unable to 
mediate the effects of rev. One of these mutants, 
pMr-3, produced a truncated rev polypeptide in which 
the first 17 amino acids were lacking [lo]. We found 
that the fusion protein from pRVA with a similar N- 
terminal deletion shows diminished binding of RNA in 
the precipitation assay, and it reacts equally to pRBV 
in Northwestern blots. This may indicate that the loss 
of rev activity in the eukaryotic deletion variant could 
have a correlation with diminished RNA binding in 
vitro. The polypeptide from pRVA does not contain 
the 12 amino acids of the rev protein carboxy-terminus. 
Two studies have shown that this part of the protein is 
not required for the function of rev [8, lo]. The nuclear 
targeting sequence of rev, a basophilic region between 
amino acids 38 and 45 [8,10], appears not to be suffi- 
cient for RNA binding. The recent study by Daly et al. 
demonstrated 50% binding inhibition of rev and RRE 
in sense-orientation by 2.5 x 10m4 mol/ml E. coli 
tRNA, while 7 x lo-’ mol/ml were required to achieve 
an equal inhibition by the antisense transcript. We 
found the optimal concentration for Northwestern blot 
to be 3 x 10e6 mol/ml E. coli RNA, for the im- 
munoprecipitation procedure at 3 x 10m5 mol/ml of 
the unspecific competitor. The use of E. coli fusion 
proteins, purified by a rapid method, should be advan- 
tageous in defining more precisely structural re- 
quirements for binding at the level of RNA and 
protein. 
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